{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:11:18Z","timestamp":1767373878496,"version":"3.37.3"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Research on Regulatory Science of Pharmaceuticals and Medical Devices of the Japan Agency for Medical Research and Development","award":["JP18mk0104117","JP21mk0101189"],"award-info":[{"award-number":["JP18mk0104117","JP21mk0101189"]}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP20fk0108263"],"award-info":[{"award-number":["JP20fk0108263"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS KAKENHI","award":["21H02634"],"award-info":[{"award-number":["21H02634"]}]},{"DOI":"10.13039\/501100004330","name":"Smoking Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Coronavirus disease 2019 (COVID-19) continues to spread across the globe, with numerous clinical trials underway seeking to develop and test effective COVID-19 therapies, including remdesivir. Several ongoing studies have reported hydroxychloroquine-induced cardiotoxicity, including development of torsade de pointes (TdP). Meanwhile, human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are expected to serve as a tool for assessing drug-induced cardiotoxicity, such as TdP and contraction impairment. However, the cardiotoxicity of COVID-19 treatments has not been fully assessed using hiPSC-CMs. In this study, we focused on drug repurposing with various modes of actions and examined the TdP risk associated with COVID-19 treatments using field potential using multi-electrode array system and motion analysis with hiPSC-CMs. Hydroxychloroquine induced early after depolarization, while remdesivir, favipiravir, camostat, and ivermectin had little effect on field potentials. We then analyzed electromechanical window, which is defined as the difference between field potential and contraction-relaxation durations. Hydroxychloroquine decreased electromechanical window of hiPSC-CMs in a concentration-dependent manner. In contrast, other drugs had little effect. Our data suggest that hydroxychloroquine has proarrhythmic risk and other drugs have low proarrhythmic risk. Thus, hiPSC-CMs represent a useful tool for assessing the comprehensive cardiotoxicity caused by COVID-19 treatments in nonclinical settings.<\/jats:p>","DOI":"10.1093\/toxsci\/kfab079","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T11:12:21Z","timestamp":1623841941000},"page":"227-239","source":"Crossref","is-referenced-by-count":17,"title":["Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes"],"prefix":"10.1093","volume":"183","author":[{"given":"Shota","family":"Yanagida","sequence":"first","affiliation":[{"name":"Division of Pharmacology, National Institute of Health Sciences (NIHS), Kawasaki, Kanagawa 210-9501, Japan"},{"name":"Division of Pharmaceutical Sciences, Graduated School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayano","family":"Satsuka","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, National Institute of Health Sciences (NIHS), Kawasaki, Kanagawa 210-9501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayo","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, National Institute of Health Sciences (NIHS), Kawasaki, Kanagawa 210-9501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5056-0442","authenticated-orcid":false,"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, Graduated School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, National Institute of Health Sciences (NIHS), Kawasaki, Kanagawa 210-9501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"2021083017204049000_kfab079-B1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.vascn.2016.12.003","article-title":"A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes","volume":"84","author":"Ando","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2021083017204049000_kfab079-B2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vascn.2015.04.002","article-title":"Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes","volume":"75","author":"Asakura","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2021083017204049000_kfab079-B3","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2014 Final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"2021083017204049000_kfab079-B4","first-page":"20875","article-title":"The role of TMPRSS2-inhibitor camostat in the pathogenesis of COVID-19 in lung cells","volume":"27","author":"Bittmann","year":"2020","journal-title":"Biomed. J. Sci. Tech. Res"},{"key":"2021083017204049000_kfab079-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10557-018-06847-9","article-title":"Revisiting the cardiotoxic effect of chloroquine","volume":"33","author":"Blignaut","year":"2019","journal-title":"Cardiovasc. Drugs Ther"},{"key":"2021083017204049000_kfab079-B6","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment","volume":"24","author":"Blinova","year":"2018","journal-title":"Cell Rep"},{"key":"2021083017204049000_kfab079-B7","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"2021083017204049000_kfab079-B8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1378\/chest.80.5.613","article-title":"Linear relationship between electrical systole, mechanical systole, and heart rate","volume":"80","author":"Boudoulas","year":"1981","journal-title":"Chest"},{"key":"2021083017204049000_kfab079-B9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/bcpt.13533","article-title":"Camostat mesylate against SARS-CoV-2 and COVID-19 - Rationale, dosing and safety","volume":"128","author":"Breining","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol"},{"key":"2021083017204049000_kfab079-B10","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.hrthm.2015.05.027","article-title":"Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential","volume":"12","author":"Capel","year":"2015","journal-title":"Heart Rhythm"},{"key":"2021083017204049000_kfab079-B11","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"2021083017204049000_kfab079-B12","doi-asserted-by":"crossref","first-page":"100720","DOI":"10.1016\/j.eclinm.2020.100720","article-title":"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial","volume":"32","author":"Chaccour","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2021083017204049000_kfab079-B13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","article-title":"Cardiac complications attributed to chloroquine and hydroxychloroquine: A systematic review of the literature","volume":"41","author":"Chatre","year":"2018","journal-title":"Drug Saf"},{"key":"2021083017204049000_kfab079-B14","doi-asserted-by":"crossref","first-page":"104955","DOI":"10.1016\/j.antiviral.2020.104955","article-title":"Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes","volume":"184","author":"Choi","year":"2020","journal-title":"Antiviral Res"},{"key":"2021083017204049000_kfab079-B15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.hrthm.2020.05.014","article-title":"QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine\/azithromycin","volume":"17","author":"Chorin","year":"2020","journal-title":"Heart Rhythm"},{"key":"2021083017204049000_kfab079-B16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/cts.13011","article-title":"Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19","volume":"14","author":"Delaunois","year":"2021","journal-title":"Clin. Transl. Sci"},{"key":"2021083017204049000_kfab079-B17","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3899\/jrheum.150379","article-title":"Hydroxychloroquine blood levels in systemic lupus erythematosus: Clarifying dosing controversies and improving adherence","volume":"42","author":"Durcan","year":"2015","journal-title":"J. Rheumatol"},{"key":"2021083017204049000_kfab079-B18","doi-asserted-by":"crossref","first-page":"m1432","DOI":"10.1136\/bmj.m1432","article-title":"Chloroquine and hydroxychloroquine in covid-19","volume":"369","author":"Ferner","year":"2020","journal-title":"BMJ"},{"key":"2021083017204049000_kfab079-B19","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"2021083017204049000_kfab079-B20","doi-asserted-by":"crossref","first-page":"104756","DOI":"10.1016\/j.yrtph.2020.104756","article-title":"Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations","volume":"117","author":"Gintant","year":"2020","journal-title":"Regul. Toxicol. Pharmacol"},{"key":"2021083017204049000_kfab079-B21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1476-5381.2011.01795.x","article-title":"The electro-mechanical window in anaesthetized guinea pigs: A new marker in screening for Torsade de Pointes risk","volume":"166","author":"Guns","year":"2012","journal-title":"Br. J. Pharmacol"},{"key":"2021083017204049000_kfab079-B22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.vascn.2009.07.002","article-title":"Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates","volume":"60","author":"Guo","year":"2009","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2021083017204049000_kfab079-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.00884","article-title":"Considerations for an in vitro, cell-based testing platform for detection of adverse drug-induced inotropic effects in early drug development. Part 1: General considerations for development of novel testing platforms","volume":"10","author":"Guth","year":"2019","journal-title":"Front. Pharmacol"},{"key":"2021083017204049000_kfab079-B24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yjmcc.2014.09.010","article-title":"Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology","volume":"77","author":"Hayakawa","year":"2014","journal-title":"J. Mol. Cell Cardiol"},{"key":"2021083017204049000_kfab079-B25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2131\/jts.43.493","article-title":"Conduction and contraction properties of human iPS cell-derived cardiomyocytes: Analysis by motion field imaging compared with the guinea-pig isolated heart model","volume":"43","author":"Isobe","year":"2018","journal-title":"J. Toxicol. Sci"},{"key":"2021083017204049000_kfab079-B26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2131\/jts.44.859","article-title":"Cardiac safety assessment with motion field imaging analysis of human iPS cell-derived cardiomyocytes is improved by an integrated evaluation with cardiac ion channel profiling","volume":"44","author":"Isobe","year":"2019","journal-title":"J. Toxicol. Sci"},{"key":"2021083017204049000_kfab079-B27","first-page":"ciaa1176","article-title":"AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): Interim results of a phase II\/III multicenter randomized clinical trial","author":"Ivashchenko","year":"2020","journal-title":"Clin. Infect. Dis"},{"key":"2021083017204049000_kfab079-B28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2131\/jts.42.183","article-title":"Characterization of human iPS cell-derived cardiomyocyte sheets as a model to detect drug-induced conduction disturbance","volume":"42","author":"Izumi-Nakaseko","year":"2017","journal-title":"J. Toxicol. Sci"},{"key":"2021083017204049000_kfab079-B29","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.hrthm.2020.05.008","article-title":"QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review","volume":"17","author":"Jankelson","year":"2020","journal-title":"Heart Rhythm"},{"key":"2021083017204049000_kfab079-B30","doi-asserted-by":"crossref","first-page":"100773","DOI":"10.1016\/j.eclinm.2021.100773","article-title":"Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial","volume":"33","author":"Johnston","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2021083017204049000_kfab079-B31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehs418","article-title":"Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets","volume":"34","author":"Kadota","year":"2013","journal-title":"Eur. Heart J"},{"key":"2021083017204049000_kfab079-B32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jphs.2018.10.010","article-title":"Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update","volume":"138","author":"Kanda","year":"2018","journal-title":"J. Pharmacol. Sci"},{"key":"2021083017204049000_kfab079-B33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2015.12.002","article-title":"CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia - Effects of 7 reference compounds at 10 facilities","volume":"78","author":"Kitaguchi","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2021083017204049000_kfab079-B34","first-page":"1845","article-title":"Repurposing current therapeutic regimens against SARS-CoV-2 (Review)","volume":"20","author":"Konstantinidou","year":"2020","journal-title":"Exp. Ther. Med"},{"key":"2021083017204049000_kfab079-B35","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1097\/MJT.0000000000001377","article-title":"Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19","volume":"28","author":"Kory","year":"2021","journal-title":"Am. J. Ther"},{"key":"2021083017204049000_kfab079-B36","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCRESAHA.111.262535","article-title":"Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers","volume":"110","author":"Lee","year":"2012","journal-title":"Circ. Res"},{"key":"2021083017204049000_kfab079-B37","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1093\/cvr\/cvz283","article-title":"Cardiac arrhythmogenesis: A tale of two clocks?","volume":"116","author":"Lei","year":"2020","journal-title":"Cardiovasc. Res"},{"key":"2021083017204049000_kfab079-B39","doi-asserted-by":"crossref","first-page":"n1077","DOI":"10.1136\/bmj.n1077","article-title":"Covid-19: UK launches antivirals taskforce to deliver home treatments by autumn","volume":"373","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"2021083017204049000_kfab079-B40","first-page":"1","article-title":"Remdesivir against COVID-19 and other viral diseases","volume":"34","author":"Malin","year":"2021","journal-title":"Clin. Microbiol. Rev"},{"key":"2021083017204049000_kfab079-B41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF00315548","article-title":"Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites","volume":"44","author":"McLachlan","year":"1993","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"2021083017204049000_kfab079-B42","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/toxsci\/kfs309","article-title":"Pharmacoelectrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes","volume":"131","author":"Mehta","year":"2013","journal-title":"Toxicol. Sci"},{"key":"2021083017204049000_kfab079-B43","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2021083017204049000_kfab079-B44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/cts.12882","article-title":"Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs","volume":"14","author":"Michaud","year":"2021","journal-title":"Clin. Transl. Sci"},{"key":"2021083017204049000_kfab079-B45","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/art.1780300512","article-title":"Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis","volume":"30","author":"Miller","year":"1987","journal-title":"Arthritis Rheum"},{"key":"2021083017204049000_kfab079-B46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.vascn.2016.06.003","article-title":"Shortening of the electromechanical window in the ketamine\/xylazine-anesthetized guinea pig model to assess pro-arrhythmic risk in early drug development","volume":"81","author":"Morissette","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2021083017204049000_kfab079-B47","doi-asserted-by":"crossref","first-page":"e0005389","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Negl. Trop. Dis"},{"key":"2021083017204049000_kfab079-B48","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/cts.12976","article-title":"Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19. A simulation study","volume":"14","author":"Okada","year":"2021","journal-title":"Clin. Transl. Sci"},{"key":"2021083017204049000_kfab079-B49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11481-020-09923-w","article-title":"Smooth or risky revisit of an old malaria drug for COVID-19?","volume":"15","author":"Pahan","year":"2020","journal-title":"J. Neuroimmune Pharmacol"},{"key":"2021083017204049000_kfab079-B50","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1111\/bph.14786","article-title":"Drug-induced shortening of the electromechanical window is an effective biomarker for in silico prediction of clinical risk of arrhythmias","volume":"176","author":"Passini","year":"2019","journal-title":"Br. J. Pharmacol"},{"key":"2021083017204049000_kfab079-B51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","article-title":"A review of the safety of favipiravir \u2013 A potential treatment in the COVID-19 pandemic?","volume":"6","author":"Pilkington","year":"2020","journal-title":"J. Virus Erad"},{"key":"2021083017204049000_kfab079-B52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res"},{"key":"2021083017204049000_kfab079-B53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.00934","article-title":"Considerations for an in vitro, cell-based testing platform for detection of drug-induced inotropic effects in early drug development. Part 2: Designing and fabricating microsystems for assaying cardiac contractility with physiological relevance using hum","volume":"10","author":"Ribeiro","year":"2019","journal-title":"Front. Pharmacol"},{"key":"2021083017204049000_kfab079-B54","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"2021083017204049000_kfab079-B55","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00134-021-06395-1","article-title":"Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia","volume":"47","author":"Sakr","year":"2021","journal-title":"Intensive Care Med"},{"key":"2021083017204049000_kfab079-B56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/toxsci\/kfu186","article-title":"An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility","volume":"142","author":"Scott","year":"2014","journal-title":"Toxicol. Sci"},{"key":"2021083017204049000_kfab079-B57","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00228-015-1959-z","article-title":"Establishing assay sensitivity in QT studies: Experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study","volume":"71","author":"Shah","year":"2015","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"2021083017204049000_kfab079-B58","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bph.12483","article-title":"The electromechanical window is no better than QT prolongation to assess risk of Torsade de Pointes in the complete atrioventricular block model in dogs","volume":"171","author":"Stams","year":"2014","journal-title":"Br. J. Pharmacol"},{"key":"2021083017204049000_kfab079-B59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.vascn.2015.09.005","article-title":"Translational assessment of cardiac contractility by echocardiography in the telemetered rat","volume":"77","author":"Tang","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2021083017204049000_kfab079-B60","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","article-title":"Bioavailability of hydroxychloroquine tablets in healthy volunteers","volume":"27","author":"Tett","year":"1989","journal-title":"Br. J. Clin. Pharmacol"},{"key":"2021083017204049000_kfab079-B61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-2999(90)90108-I","article-title":"Depressant effects of chloroquine on the isolated guinea-pig heart","volume":"178","author":"Tona","year":"1990","journal-title":"Eur. J. Pharmacol"},{"key":"2021083017204049000_kfab079-B62","doi-asserted-by":"crossref","first-page":"791.e5","DOI":"10.1016\/j.cmi.2021.02.013","article-title":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): A new safety concerns","volume":"27","author":"Touafchia","year":"2021","journal-title":"Clin. Microbiol. Infect"},{"key":"2021083017204049000_kfab079-B63","doi-asserted-by":"crossref","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"Touret","year":"2020","journal-title":"Antiviral Res"},{"key":"2021083017204049000_kfab079-B64","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int. J. Infect. Dis"},{"key":"2021083017204049000_kfab079-B65","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.hrthm.2020.05.030","article-title":"Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine\/hydroxychloroquine for treating COVID-19","volume":"17","author":"Uzelac","year":"2020","journal-title":"Heart Rhythm"},{"key":"2021083017204049000_kfab079-B66","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1476-5381.2010.00934.x","article-title":"The Electro-Mechanical window: A risk marker for torsade de pointes in a canine model of drug induced arrhythmias","volume":"161","author":"van der Linde","year":"2010","journal-title":"Br. J. Pharmacol"},{"key":"2021083017204049000_kfab079-B67","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2131\/jts.42.519","article-title":"Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes","volume":"42","author":"Watanabe","year":"2017","journal-title":"J. Toxicol. Sci"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfab079\/39543343\/kfab079.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/toxsci\/article-pdf\/183\/1\/227\/40084558\/kfab079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/toxsci\/article-pdf\/183\/1\/227\/40084558\/kfab079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T17:21:47Z","timestamp":1630344107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/183\/1\/227\/6303628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6,17]]},"published-print":{"date-parts":[[2021,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfab079","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"type":"print","value":"1096-6080"},{"type":"electronic","value":"1096-0929"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,6,17]]}}}